Retatrutide, from Soma, represents a exciting advance in metabolic control . This dual-action compound combines hormonal receptor agonist activity with gut-derived receptor agonist activation , indicating substantial results in patient findings for metabolic reduction . Experts believe this treatment is expected to provide a new pathway for patient